Asahi Kasei Corp
F:ASAA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Asahi Kasei Corp
F:ASAA
|
JP |
|
Ecolab Inc
NYSE:ECL
|
US |
|
M
|
Masimo Corp
F:3M4
|
US |
|
N
|
Northwest Pipe Co
XBER:NW7
|
US |
|
C
|
Chorus Ltd
OTC:CHRUF
|
NZ |
|
C
|
CenterPoint Energy Inc
XBER:HOU
|
US |
|
Columbus McKinnon Corp
NASDAQ:CMCO
|
US |
|
Sleep Country Canada Holdings Inc
F:1S2
|
CA |
|
National Health Investors Inc
NYSE:NHI
|
US |
|
C
|
Ciena Corp
F:CIE1
|
US |
|
K
|
Kuala Lumpur Kepong Bhd
KLSE:KLK
|
MY |
|
T
|
Tyler Technologies Inc
F:TYP
|
US |
|
C
|
Curro Holdings Ltd
JSE:COH
|
ZA |
|
H
|
Henkel AG & Co KGaA
OTC:HENOY
|
DE |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
US |
|
W
|
Whirlpool Corp
BMV:WHR
|
US |
|
S
|
Standard Chartered PLC
OTC:SCBFY
|
UK |
|
Universal Scientific Industrial Shanghai Co Ltd
SSE:601231
|
CN |
Asahi Kasei Corp
Asahi Kasei is a Japanese industrial company that makes materials, chemicals, and healthcare products. It sells items such as plastics, fibers, membranes, and specialty materials used in cars, electronics, construction, and everyday consumer goods. It also has a healthcare business that supplies drugs, diagnostic tools, and critical care products to hospitals and medical professionals. The company makes money by selling these products to manufacturers, builders, healthcare providers, and government or industrial buyers. In its materials businesses, Asahi Kasei often sits in the middle of the supply chain: it turns raw inputs into high-value components that other companies use in their own products. In healthcare, it earns revenue from products and systems that are bought through medical channels and used directly in patient care. What makes Asahi Kasei different is that it combines heavy industrial chemistry with medical and life-science businesses under one roof. That mix gives it exposure to both cyclical manufacturing demand and more stable healthcare demand. For beginners, the key idea is simple: this is not a single-product company, but a maker of specialized industrial and medical products that many other businesses and institutions rely on.
Asahi Kasei is a Japanese industrial company that makes materials, chemicals, and healthcare products. It sells items such as plastics, fibers, membranes, and specialty materials used in cars, electronics, construction, and everyday consumer goods. It also has a healthcare business that supplies drugs, diagnostic tools, and critical care products to hospitals and medical professionals.
The company makes money by selling these products to manufacturers, builders, healthcare providers, and government or industrial buyers. In its materials businesses, Asahi Kasei often sits in the middle of the supply chain: it turns raw inputs into high-value components that other companies use in their own products. In healthcare, it earns revenue from products and systems that are bought through medical channels and used directly in patient care.
What makes Asahi Kasei different is that it combines heavy industrial chemistry with medical and life-science businesses under one roof. That mix gives it exposure to both cyclical manufacturing demand and more stable healthcare demand. For beginners, the key idea is simple: this is not a single-product company, but a maker of specialized industrial and medical products that many other businesses and institutions rely on.
Record Results: Asahi Kasei posted its highest-ever Q3 cumulative net sales, operating income, ordinary income, and net income for the April–December period.
Full-Year Guidance: The company maintained its previous full-year forecast, expecting new record highs across major financial metrics despite anticipating a sequential Q4 drop in operating income due to seasonality and supply chain disruptions.
Segment Recovery: Materials saw strong recovery, especially in automotive-related and electronic materials, while Homes benefited from overseas growth. Healthcare sales rose, but income was only slightly down due to lower ventilator shipments offset by strength in other products.
Cost Pressures: Rising feedstock and ammonia prices, higher SG&A, and increased R&D expenses were noted, though formula-based pricing limited volatility.
LIB Separators: Lithium-ion battery separator sales volume was slightly down QoQ in Q3 due to semiconductor shortages but is expected to recover in Q4. Full-year growth is now projected at low single digits.
Portfolio Transformation: Management signaled an acceleration of business portfolio transformation, including further growth in Healthcare and Specialty Solutions, and ongoing structural reforms in Basic Materials.
Shareholder Returns: The dividend forecast remains at JPY 34 per share for the full year.
